A Phase 4 interventional study of Valsartan and hydrochlorothiazide (HCTZ) - monotherapy and Valsartan and amlodipine in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 5th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2009, is one of 67 in phase 4, and was the 99th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,337 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 7th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2009, is one of 67 in phase 4, and was the 168th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
Drug: Usual care
Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
Drug: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy · Drug: Valsartan
Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
Drug: Valsartan and amlodipine · Drug: Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Drug page: Hydrochlorothiazide
Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
Drug pages: Valsartan · Amlodipine
From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
As directed by investigator
Valsartan 160mg per day to 320mg per day orally
Drug page: Hydrochlorothiazide
Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target
BP target groups were: \<= 125/75mmHg, \<= 130/80mmHg and \<= 140/90mmHg. The BP target was based on the patient's clinical risk profile as specified by National Heart Foundation of Australia guidelines.
Time frame: 26 weeks
Change in Mean Sitting Systolic Blood Pressure
The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.
Time frame: Baseline and 26 weeks
Change in Mean Sitting Diastolic Blood Pressure
The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.
Time frame: Baseline and 26 weeks
Change in Absolute Cardiovascular Risk Score
The absolute cardiovascular risk assessment uses the Framingham Risk Equation to predict risk of a cardiovascular event over the next 5 years. A score of \<10% is a low risk, 10 to 15% is a moderate risk, and \>15% is a high risk. A decrease indicates improvement.
Time frame: Baseline and 26 weeks
Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy
The rate of all adverse events by preferred terms as determined by the General Practice investigators to be related to study intervention therapy was reported. Percentage of adverse events was calculated based on the number of participants analyzed. 41 adverse events were not reported as inadequate information was supplied to allow determination of drug treatment at onset.
Time frame: 26 weeks
Number of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments
A comparison of the early responders was made based on the blood pressure measurements taken at the week 6 visit window according to gender and guideline targets. The guideline targets were: patients with renal impairment: 125/75 mmHg; patients with end-organ damage/cardiovascular disease: 130/80 mmHg; others: 140/90 mmHg.
Time frame: 26 weeks
Change in the EQ-5D Score
The EQ-5D total indexed score (AUS) measures self-reported quality of life with the following 5 dimensions: mobility (range 1,2,3), self-care (range 1,2,3), usual activity (range 1,2,3), pain/discomfort (range 1,2,3) and anxiety/depression (range 1,2,3), where a 1 indicates no problems, a 2 indicates moderate problems, and a 3 indicates severe problems. The range of possible utility scores are between -0.217 (derived from worse responses from all 5 dimensions with severe problems ie 3,3,3,3,3) and 1.000 (no problems for all 5 dimensions) for each dimension. An increase in EQ-5D indexed score (AUS) indicates improvement.
Time frame: Baseline and 26 weeks
Number of Patients With Depression
Patients with depression refers to potential depressive symptoms, not clinically diagnosed depression. The 2 question Arrol screening tool was used to determine if the patient had potential depressive symptoms. The 2 questions are: During the last month have you often been bothered by feeling down, depressed or hopeless? During the past month have you often been bothered by little interest or pleasure in doing things? The presence of potential depressive symptoms was determined by a 'yes' answer to either of these questions.
Time frame: Baseline and week 26
Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26
The CES-D score was from 0 to 30, with a higher score indicating a higher level of depression. The categories for the score are: 0 to 9 suggests no depression; 10 to 15 suggests mild depression; 16 to 24 suggests moderate depression; 24 or above suggests severe depression.
Time frame: Baseline and week 26
Participants With End Organ Disease at Baseline and Week 26
A patient was considered to have end organ damage with either of the following: 1) proteinuria (dipstick = 1+ or more or protein/creatinine ratio \> 30mg/mol or 24h urine protein \> 0.3g); 2) no proteinuria, but presence of microalbuminuria (urine albumin/creatinine ratio 3.6 to 25mg/mol(male) or 3.6 to 35mg/mol (female) detected; 3) no proteinuria or microalbuminuria, but presence of macroalbuminuria (urine albumin/creatinine ratio \> 25mg/mol(male) or \>35mg/mol (female) detected OR 4) ECG evidence of LVH (Sokolow-Lyon voltage criteria values \>= 38mm). Baseline potential for end organ damage was calculated in all 1562 randomised patients based on the criteria outlined above. If no investigation/data available, assumed no end-organ damage. It is important to note that given the limited number of ECGs at 26 weeks, between group comparisons should be limited to the two time points (baseline and 26 weeks).
Time frame: Baseline and week 26
Change in Self-care Behavior Score From Baseline to Week 26
A modified self-care behavior tool (questionnaire) was used to calculate 2 domain scales: maintenance and confidence. Each domain has a standardized score between 0 and 100. Self-care is best represented by maintenance. Confidence is an important process that moderates the relationship between self-care and outcomes. Higher index score suggests better self-care. A score of 70 or greater can be used as the cut-point to judge self-care adequacy.
Time frame: Baseline and week 26
Rate of Treatment Compliance
The rate of compliance was planned to be estimated from the quantity of unused medication returned at each scheduled visit over the entire follow-up period. Rate of compliance = (tablets supplied - tablets returned)/(tablets for 100% compliance).
Time frame: 26 weeks
Number of Patients With Major Clinical Endpoints
Major clinical endpoints measured were all-cause mortality and fatal and non-fatal cardiovascular events (e.g. acute myocardial infarction, stroke and heart failure).
Time frame: 26 weeks
| Milestone | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Started | 524 | 360 | 678 |
| Completed | 466 | 289 | 568 |
| Not completed | 58 | 71 | 110 |
| Withdrew: Adverse event | 4 | 10 | 25 |
| Withdrew: Investigator discretion | 3 | 5 | 13 |
| Withdrew: Lost to follow-up | 7 | 7 | 7 |
| Withdrew: Protocol violation | 9 | 18 | 20 |
| Withdrew: Withdrawal by subject | 32 | 22 | 43 |
| Withdrew: Includes pregnancy | 3 | 9 | 2 |
BP target groups were: \<= 125/75mmHg, \<= 130/80mmHg and \<= 140/90mmHg. The BP target was based on the patient's clinical risk profile as specified by National Heart Foundation of Australia guidelines.
| percentage of participants | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target | 27.4 | 33.0 | 37.9 |
The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.
| mmHg | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure | -10 (-11.3 to -8.8) | -11.6 (-13.1 to -10.0) | -14.4 (-15.5 to -13.2) |
The visit window was from 22 to 36 weeks. If more than one blood pressure measure was available within the specified window, then the one closest to the scheduled visit was used for analysis. If no measure was available within this window, then the last recorded BP post-randomization was used for the endpoint. Analysis of covariance model was used with the factors: baseline blood pressure, treatment and blood pressure target group at randomization.
| mmHg | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure | -5.45 (-6.2 to -4.7) | -6.9 (-7.9 to -5.9) | -8.29 (-9.0 to -7.6) |
The absolute cardiovascular risk assessment uses the Framingham Risk Equation to predict risk of a cardiovascular event over the next 5 years. A score of \<10% is a low risk, 10 to 15% is a moderate risk, and \>15% is a high risk. A decrease indicates improvement.
| percentage risk score change | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Change in Absolute Cardiovascular Risk Score | -2.6 ± 4.5 | -3.3 ± 4.6 | -3.9 ± 4.5 |
The rate of all adverse events by preferred terms as determined by the General Practice investigators to be related to study intervention therapy was reported. Percentage of adverse events was calculated based on the number of participants analyzed. 41 adverse events were not reported as inadequate information was supplied to allow determination of drug treatment at onset.
| participants | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy | 70 | 70 | 169 |
A comparison of the early responders was made based on the blood pressure measurements taken at the week 6 visit window according to gender and guideline targets. The guideline targets were: patients with renal impairment: 125/75 mmHg; patients with end-organ damage/cardiovascular disease: 130/80 mmHg; others: 140/90 mmHg.
| Participants | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Male patients with a target of <125/75 mmHg | 3 | 3 | 6 |
| Male patients with a target of <130/80 mmHg | 27 | 14 | 34 |
| Male patients with a target of <140/90 mmHg | 31 | 22 | 48 |
| Female patients with a target of <125/75 mmHg | 2 | 2 | 2 |
| Female patients with a target of <130/80 mmHg | 16 | 5 | 34 |
| Female patients with a target of <140/90 mmHg | 18 | 11 | 42 |
The EQ-5D total indexed score (AUS) measures self-reported quality of life with the following 5 dimensions: mobility (range 1,2,3), self-care (range 1,2,3), usual activity (range 1,2,3), pain/discomfort (range 1,2,3) and anxiety/depression (range 1,2,3), where a 1 indicates no problems, a 2 indicates moderate problems, and a 3 indicates severe problems. The range of possible utility scores are between -0.217 (derived from worse responses from all 5 dimensions with severe problems ie 3,3,3,3,3) and 1.000 (no problems for all 5 dimensions) for each dimension. An increase in EQ-5D indexed score (AUS) indicates improvement.
| change in EQ-5D score | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Change in the EQ-5D Score | -0.007 (-0.022 to 0.008) | 0.017 (-0.001 to 0.036) | 0.011 (-0.003 to 0.024) |
Patients with depression refers to potential depressive symptoms, not clinically diagnosed depression. The 2 question Arrol screening tool was used to determine if the patient had potential depressive symptoms. The 2 questions are: During the last month have you often been bothered by feeling down, depressed or hopeless? During the past month have you often been bothered by little interest or pleasure in doing things? The presence of potential depressive symptoms was determined by a 'yes' answer to either of these questions.
| participants | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Baseline | 154 | 96 | 185 |
| Week 26 | 129 | 78 | 151 |
The CES-D score was from 0 to 30, with a higher score indicating a higher level of depression. The categories for the score are: 0 to 9 suggests no depression; 10 to 15 suggests mild depression; 16 to 24 suggests moderate depression; 24 or above suggests severe depression.
| change in CES-D score | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26 | 1.03 ± 9.24 | -1.12 ± 10.95 | 1.19 ± 11.09 |
A patient was considered to have end organ damage with either of the following: 1) proteinuria (dipstick = 1+ or more or protein/creatinine ratio \> 30mg/mol or 24h urine protein \> 0.3g); 2) no proteinuria, but presence of microalbuminuria (urine albumin/creatinine ratio 3.6 to 25mg/mol(male) or 3.6 to 35mg/mol (female) detected; 3) no proteinuria or microalbuminuria, but presence of macroalbuminuria (urine albumin/creatinine ratio \> 25mg/mol(male) or \>35mg/mol (female) detected OR 4) ECG evidence of LVH (Sokolow-Lyon voltage criteria values \>= 38mm). Baseline potential for end organ damage was calculated in all 1562 randomised patients based on the criteria outlined above. If no investigation/data available, assumed no end-organ damage. It is important to note that given the limited number of ECGs at 26 weeks, between group comparisons should be limited to the two time points (baseline and 26 weeks).
| participants | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Baseline | 226 | 146 | 315 |
| Week 26 (N = 433, 277, 536) | 157 | 88 | 177 |
A modified self-care behavior tool (questionnaire) was used to calculate 2 domain scales: maintenance and confidence. Each domain has a standardized score between 0 and 100. Self-care is best represented by maintenance. Confidence is an important process that moderates the relationship between self-care and outcomes. Higher index score suggests better self-care. A score of 70 or greater can be used as the cut-point to judge self-care adequacy.
| Change in score | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| Maintenance score | 2.59 ± 13.56 | 2.27 ± 12.56 | 3.17 ± 12.38 |
| Confidence score (N = 422, 269, 520) | 0.93 ± 21.04 | -0.72 ± 20.04 | -0.71 ± 20.16 |
The rate of compliance was planned to be estimated from the quantity of unused medication returned at each scheduled visit over the entire follow-up period. Rate of compliance = (tablets supplied - tablets returned)/(tablets for 100% compliance).
No measurements were reported for this outcome.
Major clinical endpoints measured were all-cause mortality and fatal and non-fatal cardiovascular events (e.g. acute myocardial infarction, stroke and heart failure).
| participants | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|
| All-cause mortality | 0 | 1 | 0 |
| Non-fatal cardiovascular events | 15 | 6 | 13 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-randomization | — | 27/2,185 (1.2%) | 95/2,185 (4.3%) |
| Usual Care | — | 24/524 (4.6%) | 47/524 (9%) |
| Monotherapy (Initial Monotherapy Arm) | — | 15/360 (4.2%) | 36/360 (10%) |
| Combination (Initial Combination Therapy Arm) | — | 22/678 (3.2%) | 105/678 (15.5%) |
| Event | Pre-randomization | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|---|
| Chest painCardiac disorders | 2/2185 | 1/524 | 1/360 | 5/678 |
| DyspnoeaCardiac disorders | 0/2185 | 3/524 | 1/360 | 4/678 |
| Angina pectorisCardiac disorders | 1/2185 | 3/524 | 1/360 | 0/678 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/2185 | 0/524 | 2/360 | 0/678 |
| Chest discomfortCardiac disorders | 0/2185 | 2/524 | 0/360 | 0/678 |
| SyncopeCardiac disorders | 1/2185 | 2/524 | 0/360 | 0/678 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/2185 | 2/524 | 0/360 | 0/678 |
| Oedema peripheralGeneral disorders | 0/2185 | 0/524 | 0/360 | 2/678 |
| Acute myocardial infarctionCardiac disorders | 1/2185 | 1/524 | 1/360 | 0/678 |
| Angina unstableCardiac disorders | 0/2185 | 0/524 | 1/360 | 0/678 |
| Event | Pre-randomization | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) |
|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 20/2185 | 27/524 | 9/360 | 67/678 |
| DizzinessCardiac disorders | 77/2185 | 23/524 | 28/360 | 42/678 |
| Age Continuous(years) | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) | Total |
|---|---|---|---|---|
| Mean | 59 ± 12 | 59 ± 12 | 59 ± 12 | 59 ± 12 |
| Sex: Female, Male(Participants) | Usual Care | Monotherapy (Initial Monotherapy Arm) | Combination (Initial Combination Therapy Arm) | Total |
|---|---|---|---|---|
| Female | 201 | 138 | 260 | 599 |
| Male | 323 | 222 | 418 | 963 |
The record gives a start of Jul 2009, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine · Hydrochlorothiazide